A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. (Q41701813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Carmen Balaña

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

J M Sepúlveda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

C Belda-Iniesta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

M Gil-Gil

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

P Pérez-Segura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

A Berrocal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

O Gallego

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J Capellades

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

J M Ordoñez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

B La Orden

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

2 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Translational Oncology

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

743-750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-015-1304-0

16 February 2020

exact match

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Value of surgical intervention in the treatment of glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-015-1304-0

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

12 December 2020

Isolation of genomic DNA

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S12094-015-1304-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26033428%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference